替比夫定联合胸腺法新对乙肝肝硬化代偿期患者的疗效观察.docVIP

替比夫定联合胸腺法新对乙肝肝硬化代偿期患者的疗效观察 　　【摘要】 目的 分析乙型肝炎（乙肝）肝硬化患者应用替比夫定联合胸腺法新治疗的疗效及对肝纤维化指标的影响。方法 86例代偿期乙肝肝硬化患者， 随机分为观察组和对照组， 各43例。对照组单用替比夫定治疗， 观察组给予替比夫定联合胸腺法新治疗。比较两组的治疗效果。结果 治疗48周后， 观察组肝功能及肝纤维化指标均优于对照组， 差异均有统计学意义（P0.05）， 其中， 谷丙转氨酶（ALT）、谷草转氨酶（AST）改善最显著。治疗48周后观察组乙肝病毒脱氧核糖核酸（HBV-DNA）、乙肝e抗原（HBeAg）、乙肝核心抗体（HBcAb）阴转情况（42、19、8例）均优于对照组（36、10、2例）， 差异有统计学意义（P0.05）。结论 替比夫定联合胸腺法新在改善乙肝肝硬化患者的肝功能及肝纤维化方面效果较佳， 且抗病毒能力较强， 改善患者预后， 取得较为满意的临床疗效。 　　【关键词】 替比夫定；胸腺法新；乙型肝炎肝硬化；疗效 　　DOI：10.14163/j.cnki.11-5547/r.2016.28.005 　　【Abstract】 Objective To analyze curative effect by telbivudine combined with thymalfasin for patients with hepatitis B cirrhosis， and influence on hepatic fibrosis index. Methods A total of 86 patients with compensated stage of hepatitis B cirrhosis were randomly divided into observation group and control group， with 43 cases in each group. The control group received telbivudine alone for treatment， and the observation group received telbivudine combined with thymalfasin. Curative effects were compared between the two groups. Results After 　　48 weeks of treatment， the observation group had all better liver function and liver fibrosis indexes than the control group， and their differences all had statistical significance （P0.05）， with remarkable improvement of alanine transaminas （ALT） and aspartate aminotransferase （AST）. The observation group also had better hepatitis B virus deoxyribose nucleic acid （HBV-DNA）， hepatitis B e antigen （HBeAg）， negative hepatitis B core antibody （HBcAb） （42， 19， 8 cases） after 48 weeks of treatment than the control group （36， 10， 2 cases）. The difference had statistical significance （P0.05）. Conclusion Combination of telbivudine and thymalfasin provides remarkable effect in improving liver function and liver fibrosis in patients with hepatitis B cirrhosis， along with strong anti-virus capability. It can improve prognosis in patients and provide satisfactory clinical effect. 　　【Key words】 Telbivudine； Thymalfasin； Hepatitis B cirrhosis； Curative ef